| Ralph L Magnusson, MD | |
|
1540 Lake St S, Forest Lake, MN 55025-2628 | |
| (651) 464-7100 | |
| (651) 982-5515 |
| Full Name | Ralph L Magnusson |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 39 Years |
| Location | 1540 Lake St S, Forest Lake, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487614566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 30149 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Lakes Health Services | Wyoming, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Clinics | 7113830142 | 658 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Entity Name | Healtheast Woodwinds Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309322 PECOS PAC ID: 9638082563 Enrollment ID: O20031107000110 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Entity Name | Healtheast St Joseph's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134186273 PECOS PAC ID: 2365348869 Enrollment ID: O20031208000245 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Entity Name | Healtheast St John's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447218482 PECOS PAC ID: 9234035742 Enrollment ID: O20031208000320 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Entity Name | Healtheast Care System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194787465 PECOS PAC ID: 7214833763 Enrollment ID: O20031208000483 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ralph L Magnusson, MD Po Box 43, Mr 10809, Minneapolis, MN 55440-0043 Ph: (612) 262-4813 | Ralph L Magnusson, MD 1540 Lake St S, Forest Lake, MN 55025-2628 Ph: (651) 464-7100 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.
They emphasized the need for intensified research at an international conference that opened today in Porto, Portugal. The conference on Patient safety research: shaping the European agenda will examine evidence showing that harm from medical care poses a substantial burden in terms of suffering and death in Europe and around the world.
› Verified 2 days ago